Nrf2 inhibitörü Brusatol, sıçanlarda anti-inflamasyon ve anti-oksidatif stres yoluyla çekal ligasyonu ve delinmeye bağlı akciğer hasarını iyileştirir
Amaç: Bu çalışmanın amacı, brusatolün sıçanlarda çekal ligasyon ve delinme CLD modelinin neden olduğu akciğer hasarı üzerine olası yararlı etkilerinin incelenmesidir.Yöntem: Bu çalışmada 32 adet Sprague Dawley erkek sıçan 4 rastgele gruba ayrıldı. Gruplar; grup 1 sham , grup 2 CLD , grup 3 DMSO ve grup 4 0.5 mg/ml brusatol olarak programlandı. Grup 1’de karın bölgesine orta hatta dikey insizyon uygulandı ve CLD modeli oluşturmadan tekrar kapatıldı. Grup 2’de 18 saat CLD yapıldı. Grup 3’e, %1 DMSO 10 gün boyunca iki günde bir periton içine 0.3 ml uygulandı. Son uygulama CLD’den 30 dakika önce yapıldı. Grup 4’e brusatol 10 gün boyunca iki günde bir periton içine 0.5 mg/ml olarak uygulandı. Son uygulama CLD’den 30 dakika önce yapıldı. CLD bittikten sonra sıçanlar sakrifiye edildi ve akciğer dokuları çıkarıldı. Bulgular: MDA, MPO, OSI, TOS, TNF-α ve IL-1β değerleri grup 2 ve 3’te, grup 1’e kıyasla anlamlı derecede yükselirken, SOD ve TAS değerleri azaldı. Antioksidan enzim aktivitesindeki artışın aksine; MDA seviyesi, MPO aktivitesi, TOS, OSI, TNF-α ve IL-1β değerleri grup 4’te grup 2 ve 3’e göre önemli ölçüde azaldı. Sonuç: Sıçanlarda CLD kaynaklı akciğer hasarına karşı brusatol etkin rol oynayabilir
Nrf2 Inhibitor Brusatol Ameliorates Cecal Ligation and Puncture-induced Lung Injury in Rats via Anti-inflammation and Anti-oxidative Stress
Objective: The aim of this study is to investigate the possible beneficial effects of brusatol on lung injury caused by cecal ligation and puncture CLP model in rats. Methods: In this study, 32 Sprague Dawley male rats were divided into 4 random groups. The groups were programmed as group 1 sham , group 2 CLP , group 3 DMSO , and group 4 0.5 mg/ml brusatol . In group 1, a midline vertical incision was applied to the abdominal region and closed again without forming a CLP model. Group 2 performed CLP for 18 hours. In group 3, 1% DMSO was administered intraperitoneally 0.3 ml once every two days for 10 days. The last application was made 30 minutes before CLP. In group 4, brusatol was administered intraperitoneally at 0.5 mg/ml once every two days for 10 days. The last application was made 30 minutes before CLP. After CLP was over, the rats were sacrificed and lung tissues were removed.Results: MDA, MPO, OSI, TOS, TNF-α and IL-1β values increased significantly in groups 2 and 3 compared to group 1, while SOD and TAS values decreased. Unlike the seviyesi, MPO aktivitesi, TOS, OSI, TNF-α ve IL-1β değerleri grup 4’te grup 2 ve 3’e göre önemli ölçüde azaldı. Sonuç: Sıçanlarda CLD kaynaklı akciğer hasarına karşı brusatol etkin rol oynayabilir
___
- 1. Russell JA. Management of sepsis. N Engl J Med.
2006;355(16):1699-713.
- 2. Nemzek JA, Hugunin KM, Opp MR. Modeling sepsis
in the laboratory: merging sound science with
animal well-being. Comp Med. 2008;58(2):120-8.
- 3. Babayigit H, Kucuk C, Sozuer E, Yazici C, Kose K,
Akgun H. Protective effect of beta-glucan on lung
injury after cecal ligation and puncture in rats.
Intensive Care Med. 2005;31(6):865-70.
- 4. Yang L, Li D, Zhuo Y, Zhang S, Wang X, Gao H.
Protective Role of Liriodendrin in Sepsis-Induced
Acute Lung Injury. Inflammation. 2016;39(5):1805-
13.
- 5. Zhai Y, Zhou X, Dai Q, Fan Y, Huang X. Hydrogenrich saline ameliorates lung injury associated with
cecal ligation and puncture-induced sepsis in rats.
Exp Mol Pathol. 2015;98(2):268-76.
- 6. Abraham E. Neutrophils and acute lung injury.
Critical care medicine. 2003;31(4 Suppl):S195-9.
- 7. Ayhan Tanyeli DGE. The Antioxidant and
Antiinflammatory Effects of Alliin on Cecal Ligation
and Puncture (CLP)-Induced Lung Injury. TJOS
Science. 2019;4(2):46-59.
- 8. Suliman HB, Carraway MS, Piantadosi CA.
Postlipopolysaccharide oxidative damage of
mitochondrial DNA. Am J Respir Crit Care Med.
2003;167(4):570-9.
- 9. Tang W, Xie J, Xu S, Lv H, Lin M, Yuan S, et al.
Novel nitric oxide-releasing derivatives of brusatol
as anti-inflammatory agents: design, synthesis,
biological evaluation, and nitric oxide release
studies. J Med Chem. 2014;57(18):7600-12.
- 10. Zhu S, Liu S, Wang L, Ding W, Sha J, Qian H, et
al. Brusatol Protects HepG2 Cells against OxygenGlucose Deprivation-Induced Injury via Inhibiting
Mitochondrial Reactive Oxygen Species-Induced
Oxidative Stress. Pharmacology. 2019:1-8.
- 11. Bu T, Wang C, Meng Q, Huo X, Sun H, Sun P, et
al. Hepatoprotective effect of rhein against
methotrexate-induced liver toxicity. Eur J
Pharmacol. 2018;834:266-73.
- 12. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin
HA, et al. Brusatol enhances the efficacy of
chemotherapy by inhibiting the Nrf2-mediated
defense mechanism. Proc Natl Acad Sci U S A.
2011;108(4):1433-8.
- 13. Xiang Y, Ye W, Huang C, Yu D, Chen H, Deng T, et
al. Brusatol Enhances the Chemotherapy Efficacy
of Gemcitabine in Pancreatic Cancer via the
Nrf2 Signalling Pathway. Oxid Med Cell Longev.
2018;2018:2360427.
- 14. Park SH, Kim JH, Ko E, Kim JY, Park MJ, Kim MJ,
et al. Resistance to gefitinib and cross-resistance
to irreversible EGFR-TKIs mediated by disruption
of the Keap1-Nrf2 pathway in human lung cancer
cells. Faseb J. 2018:fj201800011R.
- 15. Xiang Y, Ye W, Huang C, Lou B, Zhang J, Yu D, et
al. Brusatol inhibits growth and induces apoptosis
in pancreatic cancer cells via JNK/p38 MAPK/NFkappab/Stat3/Bcl-2 signaling pathway. Biochem
Biophys Res Commun. 2017;487(4):820-6.
- 16. Meng QT, Chen R, Chen C, Su K, Li W, Tang LH,
et al. Transcription factors Nrf2 and NF-kappaB
contribute to inflammation and apoptosis induced
by intestinal ischemia-reperfusion in mice. Int J
Mol Med. 2017;40(6):1731-40.
- 17. Ohkawa H, Ohishi N, Yagi K. Assay for Lipid
Peroxides in Animal-Tissues by Thiobarbituric Acid
Reaction. Anal Biochem. 1979;95(2):351-8.
- 18. Harma M, Harma M, Kocyigit A, Erel O. Increased
DNA damage in patients with complete hydatidiform
mole. Mutat Res-Gen Tox En. 2005;583(1):49-54.
- 19. Bradley PP, Priebat DA, Christensen RD, Rothstein
G. Measurement of cutaneous inflammation:
estimation of neutrophil content with an enzyme
marker. J Invest Dermatol. 1982;78(3):206-9.
- 20. Sun Y, Oberley LW, Li Y. A Simple Method for
Clinical Assay of Superoxide-Dismutase. Clin Chem.
1988;34(3):497-500.
- 21. Singer M, Deutschman CS, Seymour CW, ShankarHari M, Annane D, Bauer M, et al. The Third
International Consensus Definitions for Sepsis and
Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.
- 22. Sadowitz B, Roy S, Gatto LA, Habashi N, Nieman
G. Lung injury induced by sepsis: lessons learned
from large animal models and future directions
for treatment. Expert Rev Anti Infect Ther.
2011;9(12):1169-78.
- 23. Rubenfeld GD, Caldwell E, Peabody E, Weaver J,
Martin DP, Neff M, et al. Incidence and outcomes of
acute lung injury. N Engl J Med. 2005;353(16):1685-
93.
- 24. Maybauer MO, Maybauer DM, Herndon DN. Incidence
and outcomes of acute lung injury. N Engl J Med.
2006;354(4):416-7.
- 25. Husak L, Marcuzzi A, Herring J, Wen E, Yin L, Capan
DD, et al. National analysis of sepsis hospitalizations
and factors contributing to sepsis in-hospital
mortality in Canada. Healthcare quarterly (Toronto,
Ont). 2010;13:35-41.
- 26. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont
G, Carcillo J, Pinsky MR. Epidemiology of severe
sepsis in the United States: analysis of incidence,
outcome, and associated costs of care. Critical
care medicine. 2001;29(7):1303-10.